when will tirzepatide be approved for sleep apnea The clearance of #tirzepatide the treatment of #OSA is an important development for #SleepMedicine FDA Approves Zepbound for Sleep

Hair samples were measured for the structural characteristics of the scale layer, including thickness, the height of the scale, and diameter of the hair by scanning electron microscope (SEM, JSM-6380LV, JEOL Ltd.)

doi: 10.1111/dom.14553 64 WilsonJMNikooienejadARobinsDARoellWCRiesmeyerJSHauptAet al

Claims of proprietary formulations without published supporting data

While they do slightly increase heart rate, they still reduce overall cardiovascular risk

Here is what participants achieved on average: Mounjaro (tirzepatide 15mg) SURMOUNT-1: Week 4: approximately 2 to 3% body weight loss Week 12: approximately 7 to 8% Week 24: approximately 13 to 15% Week 52: approximately 18 to 20% Week 72 (end of trial): average 20.9% Wegovy (semaglutide 2.4mg) STEP 1: Week 4: approximately 1 to 2% body weight loss Week 12: approximately 5 to 6% Week 24: approximately 9 to 10% Week 52: approximately 12 to 14% Week 68 (end of trial): average 14.9% These are averages